Effect of toripalimab plus cetuximab combined with radiotherapy on patient with locally advanced high-grade parotid mucoepidermoid carcinoma

Oral Oncology Reports Pub Date : 2025-02-06 DOI:10.1016/j.oor.2025.100717

Yubin Wu , Ying Piao , Zhongming Wang , Jiehua Wang , Shihai Wu

{"title":"Effect of toripalimab plus cetuximab combined with radiotherapy on patient with locally advanced high-grade parotid mucoepidermoid carcinoma","authors":"Yubin Wu , Ying Piao , Zhongming Wang , Jiehua Wang , Shihai Wu","doi":"10.1016/j.oor.2025.100717","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Mucoepidermoid carcinoma (MEC) is the most common malignant tumor of the salivary glands, accounting for approximately one-third of all salivary gland tumors. Based on the proportion of epidermoid and mucous cells, MEC is classified into three grades. High-grade MEC, an extremely rare malignancy, has a higher proportion of epidermoid cells and a poorer prognosis. Currently, there has been no standard treatment for patients with positive surgical margins after parotidectomy.</div></div><div><h3>Case description</h3><div>This case report describes the successful treatment of a patient with high-grade parotid MEC and positive surgical margins using toripalimab plus cetuximab combined with radiotherapy, who achieved complete response one month after the completion of treatment.</div></div><div><h3>Conclusion</h3><div>We report a case in which a patient with locally advanced high-grade parotid MEC with R2 resection achieved a complete response after postoperative adjuvant radiotherapy combined with toripalimab and cetuximab.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100717"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772906025000056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Mucoepidermoid carcinoma (MEC) is the most common malignant tumor of the salivary glands, accounting for approximately one-third of all salivary gland tumors. Based on the proportion of epidermoid and mucous cells, MEC is classified into three grades. High-grade MEC, an extremely rare malignancy, has a higher proportion of epidermoid cells and a poorer prognosis. Currently, there has been no standard treatment for patients with positive surgical margins after parotidectomy.

Case description

This case report describes the successful treatment of a patient with high-grade parotid MEC and positive surgical margins using toripalimab plus cetuximab combined with radiotherapy, who achieved complete response one month after the completion of treatment.

Conclusion

We report a case in which a patient with locally advanced high-grade parotid MEC with R2 resection achieved a complete response after postoperative adjuvant radiotherapy combined with toripalimab and cetuximab.

查看原文本刊更多论文

托利帕利单抗联合西妥昔单抗联合放疗治疗局部晚期高级别腮腺粘液表皮样癌的疗效

粘液表皮样癌（MEC）是唾液腺最常见的恶性肿瘤，约占所有唾液腺肿瘤的三分之一。根据表皮样细胞和黏液细胞的比例，MEC可分为三个等级。重度MEC是一种极为罕见的恶性肿瘤，其表皮样细胞比例较高，预后较差。目前，对于腮腺切除术后切缘阳性的患者，尚无标准的治疗方法。病例描述：本病例报告描述了一名高度腮腺MEC和手术切缘阳性的患者使用托利莫单抗加西妥昔单抗联合放疗的成功治疗，该患者在治疗完成一个月后达到完全缓解。结论我们报告了一例局部晚期高级别腮腺MEC R2切除患者，术后辅助放疗联合托利莫单抗和西妥昔单抗治疗后完全缓解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oral Oncology Reports

CiteScore

0.20

自引率

0.00%

发文量